736 related articles for article (PubMed ID: 27982454)
21. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
23. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Mato AR; Roeker LE; Eyre TA; Nabhan C; Lamanna N; Hill BT; Brander DM; Barr PM; Lansigan F; Cheson BD; Singavi AK; Yazdy MS; Shah NN; Allan JN; Bhavsar EB; Rhodes J; Kennard K; Schuster SJ; Williams AM; Skarbnik AP; Goy AH; Goodfriend JM; Dorsey C; Coombs CC; Tuncer H; Ujjani CS; Jacobs R; Winter AM; Pagel JM; Bailey N; Schuh A; Shadman M; Sitlinger A; Weissbrot H; Muralikrishnan S; Zelenetz A; Kirkwood AA; Fox CP
Blood Adv; 2019 May; 3(10):1568-1573. PubMed ID: 31101647
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
25. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
26. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract][Full Text] [Related]
27. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
29. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Salem AH; Dunbar M; Agarwal SK
Anticancer Drugs; 2017 Sep; 28(8):911-914. PubMed ID: 28562380
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
36. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
38. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland.
Barbier M; Durno N; Bennison C; Örtli M; Knapp C; Schwenkglenks M
Eur J Health Econ; 2022 Jul; 23(5):837-846. PubMed ID: 34757508
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]